A new pill, tavapadon, has shown potential in easing Parkinson’s symptoms while limiting side effects. In patients taking at ...

Two studies published in Nature found stem cell-derived products can not only be safely transplanted into the brain, but also ...

The highly selective partial agonist at D1 and D5 receptors significantly improves motor function in patients recently ...

Significant reduction also seen in change from baseline in daily OFF times vs placebo. HealthDay News — For patients with Parkinson disease with motor fluctuations, the oral once-daily ...

This milestone is a testament to King’s College Hospital Dubai’s unwavering dedication to offering groundbreaking, patient-centered care.

For patients with Parkinson's disease with motor fluctuations, the oral once-daily, selective D1/D5 partial dopamine agonist tavapadon as an adjunct to levodopa increases total daily ON time ...

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not ...

The study focused on oral levodopa for Parkinson's and insulin for diabetes, as these are common in patients in A&E and must be given on time. Researchers used data from 136 emergency departments in ...

Until now, levodopa has been the standard first-line treatment for Parkinson’s patients. Levodopa — which is converted into dopamine in the brain and targets the D2/D3/D4 dopamine receptors ...

Until now, levodopa has been the standard first-line treatment for Parkinson’s patients. Levodopa — which is converted into dopamine in the brain and targets the D2/D3/D4 dopamine receptors ...